News for MeiraGTx Holdings plc (MGTX)

On July 8, 2025, Alexandria Forbes, President & CEO of MeiraGTx Holdings PLC, executed a sale of 47,500 shares of the company (symbol: MGTX). Following this tra

Lucid Capital has begun coverage of MeiraGTx (MGTX) with a Buy rating and set a target price of $50. According to an analyst at the firm, MeiraGTx focuses on ad

On March 31, 2025, Prosight Management, LP (Trades, Portfolio) made a strategic decision to reduce its stake in MeiraGTx Holdings PLC by 34,266 shares. The tran

On May 14, 2025, Chardan Capital released an update on its analyst rating for MeiraGTx Holdings (MGTX), providing important insights for investors. Analyst Dani

Revenue: $1.9 million for Q1 2025, falling short of the estimated $4.43 million.Earnings Per Share (EPS): Reported a net loss of $0.51 per share, missing the e

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy LONDON and NEW YORK, May 13, 2025

MeiraGTx (MGTX) presented at ASGCT 2025, showcasing key advancements in gene therapy. Highlights include 40% weight loss in mice using an optimized BDNF

MeiraGTx (MGTX) delivered earnings and revenue surprises of -34.21% and 76.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Key Highlights: MeiraGTx (MGTX) gains RMAT designation for its promising Parkinson's disease therapy. Analysts suggest a potential upside of 334.62% with

- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease

**media[620338]**

MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson’s Disease, and xerostomia, with multiple assets in advanced clinical stages showing...

We recently published a list of Top 10 AI News Updates Taking Wall Street By Storm.

U.S. stocks traded lower midway through trading, with the S&P 500 falling more than 1% on Thursday. The Dow traded down 1.17% to 40,865.63 while the NASDAQ dip...

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of G-III Apparel Group, Ltd. GIII gained 13.9% to $28.87 after t...

New York-based Y-mAbs Therapeutics, Inc. (YMAB) is down over 26 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $

- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen N

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.